CRIS Current Research Information System

GELSOMINO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.792
NA - Nord America 2.253
EU - Europa 1.483
SA - Sud America 164
AF - Africa 163
Continente sconosciuto - Info sul continente non disponibili 149
OC - Oceania 3
Totale 7.007
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.205
CN - Cina 778
VN - Vietnam 759
SG - Singapore 627
IT - Italia 515
HK - Hong Kong 186
GB - Regno Unito 175
SE - Svezia 174
DE - Germania 151
BR - Brasile 127
IN - India 96
NL - Olanda 88
FR - Francia 85
BD - Bangladesh 84
KR - Corea 70
IE - Irlanda 56
FI - Finlandia 47
RU - Federazione Russa 46
TG - Togo 44
CI - Costa d'Avorio 40
JP - Giappone 39
JO - Giordania 28
CH - Svizzera 25
ZA - Sudafrica 25
CA - Canada 24
BG - Bulgaria 21
UA - Ucraina 20
PH - Filippine 19
BE - Belgio 16
MX - Messico 16
TH - Thailandia 15
ID - Indonesia 13
TR - Turchia 13
PL - Polonia 12
DZ - Algeria 11
EE - Estonia 11
SC - Seychelles 11
EC - Ecuador 10
IQ - Iraq 10
PK - Pakistan 10
EG - Egitto 9
VE - Venezuela 9
AR - Argentina 8
AT - Austria 8
ES - Italia 8
NG - Nigeria 8
TW - Taiwan 8
IL - Israele 5
MY - Malesia 5
CL - Cile 4
HR - Croazia 4
IR - Iran 4
LB - Libano 4
TN - Tunisia 4
UZ - Uzbekistan 4
AU - Australia 3
KE - Kenya 3
LT - Lituania 3
OM - Oman 3
UY - Uruguay 3
AL - Albania 2
AZ - Azerbaigian 2
CO - Colombia 2
CZ - Repubblica Ceca 2
KG - Kirghizistan 2
MA - Marocco 2
MK - Macedonia 2
MU - Mauritius 2
PA - Panama 2
PT - Portogallo 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BY - Bielorussia 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
GA - Gabon 1
GR - Grecia 1
HN - Honduras 1
JM - Giamaica 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MD - Moldavia 1
NI - Nicaragua 1
NO - Norvegia 1
NP - Nepal 1
PY - Paraguay 1
RS - Serbia 1
TT - Trinidad e Tobago 1
UG - Uganda 1
Totale 6.859
Salva come PNG Salva come JPEG
Città #
Singapore 458
Ashburn 303
Hong Kong 176
Shanghai 175
San Jose 172
Ho Chi Minh City 150
Fairfield 142
Dong Ket 140
Hanoi 139
Southend 137
Hefei 133
Chandler 118
Bologna 96
Houston 86
Santa Clara 85
Council Bluffs 83
Woodbridge 82
Beijing 79
Seoul 67
Seattle 63
Dallas 54
Dublin 54
Los Angeles 54
Princeton 53
Cambridge 51
Wilmington 51
Lomé 44
Ann Arbor 42
Boardman 41
Abidjan 40
Milan 40
Lauterbourg 35
Helsinki 34
Turin 33
New York 30
Tokyo 27
Amman 26
São Paulo 25
Da Nang 24
Florence 24
Bern 21
Nanjing 20
Redmond 20
Redondo Beach 20
Sofia 18
Haiphong 17
Buffalo 16
Frankfurt am Main 16
Jinan 16
San Diego 16
Brussels 15
Westminster 14
Bengaluru 12
Chicago 12
Modena 12
Shenyang 12
Algiers 11
Biên Hòa 11
Falkenstein 11
Hải Dương 11
Johannesburg 11
Phoenix 11
Berlin 10
Des Moines 10
Montreal 10
Naples 10
Bremen 9
Can Tho 9
Guangzhou 9
Lappeenranta 9
Medford 9
Orem 9
Tianjin 9
Visakhapatnam 9
Abeokuta 8
Amsterdam 8
Bắc Giang 8
Kyiv 8
Nanchang 8
The Dalles 8
Warsaw 8
Bangkok 7
Bühl 7
Hangzhou 7
Jakarta 7
Kerpen 7
Mexico City 7
Ninh Bình 7
Redwood City 7
Shenzhen 7
Atlanta 6
Bari 6
Boydton 6
Charlotte 6
Denver 6
Ha Long 6
Hyderabad 6
London 6
Padova 6
Quận Một 6
Totale 4.280
Salva come PNG Salva come JPEG
Nome #
IFN-γ and CD38 in Hyperprogressive Cancer Development 442
A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event 342
STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status 294
Next-generation technologies in predictive molecular pathology of lung cancers 246
PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD) 245
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors 245
Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial 232
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience 209
Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding 206
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) 204
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players? 196
Pembrolizumab in the treatment of metastatic non-small cell lung cancer: A review of current evidence 192
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma 188
Nivolumab-induced cholangitic liver disease: A novel form of serious liver injury 187
18F-FLT PET/CT in patients with advanced Non-Small Lung Cancer (NSCLC) treated with Nivolumab: preliminary results 185
Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer 180
Complete Recalcification Following Arterial Embolization of Massive Osteolytic Bone Metastasis From NSCLC 177
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016 175
Peripheral nervous system adverse events associated with immune checkpoint inhibitors 174
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC 174
Immune-mediated cholangitis: is it always nivolumab’s fault? 173
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance 168
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO) 167
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies 166
New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event 163
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System 162
Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study 160
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 157
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 156
Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer 154
Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report 148
The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers 135
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) 132
EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature 107
Programmed death-1 inhibition and atherosclerosis: Can nivolumab vanish complicated atheromatous plaques? 93
null 75
Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC 66
Plasma genotyping for EGFR T790M in non-small cell lung cancer: Ready for clinical practice? 57
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis 45
Letter Re: Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations 30
Totale 7.007
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.702
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.702
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022475 0 17 26 22 59 30 20 27 46 31 122 75
2022/2023678 49 110 52 71 34 47 26 44 126 17 64 38
2023/2024422 24 25 15 19 17 57 13 189 12 22 24 5
2024/20251.099 60 123 75 49 111 59 73 33 10 130 99 277
2025/20262.974 329 330 215 211 230 163 304 102 541 256 149 144
2026/2027220 112 108 0 0 0 0 0 0 0 0 0 0
Totale 7.007